CombiMatrix Corporation Receives Grant from National Institutes of Health for Continued Development of Its Protein Biochip Technology.Business Editors & Health/Medical Writers BIOWIRE2K MUKILTEO, Wash.--(BW HealthWire)--Feb. 20, 2002 CombiMatrix Corporation, a majority owned subsidiary of Acacia Research Corporation (Nasdaq:ACRI), announced today that it has been awarded a Phase I NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. grant for the development of its protein biochip technology. The title of the grant is "Self-Assembling Protein Microchips." This grant is in addition to a three-year Phase I and a Phase II SBIR SBIR Small Business Innovation Research (program/grant) SBIR Space Based Infra-Red SBIR Speaker-Boundary Interference SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) Grant from the U.S. Department of Defense for the development of multiplexed chip based assays for chemical and biological warfare agent detection. "The first application of CombiMatrix' microelectrode mi·cro·e·lec·trode n. A very small electrode, often used to study electrical characteristics of living cells and tissues. microelectrode, n array technology is for genetic analysis," stated Dr. Amit Kumar, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CombiMatrix. "We are now in rapid development of protein synthesis and analysis tools utilizing our core technology. The NIH grant as well as the previous Department of Defense grant is validation of our approach. As we advance our product development, we anticipate working with corporate partners to accelerate commercialization of our products in several proteomic market segments." CombiMatrix' technology enables highly parallel translation and immobilization Immobilization Definition Immobilization refers to the process of holding a joint or bone in place with a splint, cast, or brace. This is done to prevent an injured area from moving while it heals. of multiple proteins on a chip, from RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic , as well as subsequent high-throughput analysis of such immobilized proteins. The approach couples CombiMatrix' active semiconductor-based microarray technology with conventional cell-free translation methods to provide a flexible and powerful platform for protein research. About CombiMatrix CombiMatrix is developing a platform technology that has a wide range of applications, from DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics to immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. The platform allows the company to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The company is designing its products principally to be responsive to the needs of pharmaceutical, biotechnology, and academic researchers in analyzing raw genomic data in the discovery and development of pharmaceutical products. CombiMatrix' Web site is located at www.combimatrix.com. About Acacia Research Corporation Acacia Research develops, licenses and provides products for the life science and media technology sectors. Acacia licenses its V-chip technology to television manufacturers and owns pioneering technology for digital streaming and video-on-demand. Acacia's CombiMatrix subsidiary is developing a bio-chip technology for the life science market. Acacia Research's website is located at www.acaciaresearch.com. Safe Harbor Statement under the Private Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion